Perioperative high dose rate brachytherapy in previously irradiated head and neck cancer: Results of a phase I/II reirradiation study
Martínez-Fernández MI (1), Alcalde J (2), Cambeiro M (1), Peydró GV (1), Martínez-Monge R (3).
(1) Department of Oncology, Clínica Universidad de Navarra, Spain.
(2) Department of Otolaryngology, Clínica Universidad de Navarra, Spain.
(3) Department of Oncology, Clínica Universidad de Navarra, Spain.
BACKGROUND AND PURPOSE:
This study was undertaken to determine the feasibility of salvage surgery and PHDRB in patients with previously irradiated, recurrent head and neck cancer or second primary tumors arising in a previously irradiated field.
METHODS AND MATERIALS:
Sixty-three patients were treated with surgical resection and PHDRB. The PHDRB dose was 4Gy b.i.d.×8 (32Gy) for R0 resections and 4Gy b.i.d.×10 (40Gy) for R1 resections, respectively. Further external beam radiotherapy or chemotherapy was not given.
Resections were categorized as R0 in 7 patients (11.1%) and R1 in 56 (88.9%). Thirty-four patients with R1 resections (54.0%) had microscopically positive margins, and 22 patients (34.9%) had close margins.
Thirty-two patients (50.8%) developed RTOG grade 3 or greater adverse events including 3 fatal events. After a median follow-up of 6.8years, the 5-year locoregional control rate and 5-year overall survival rates were 55.0% and 35.6%, respectively.
Surgical resection and PHDRB is a successful treatment strategy in selected patients with previously irradiated head and neck cancer. Long-term locoregional control can be achieved in a substantial number of cases despite a high rate of inadequate surgical resections although at the expense of substantial toxicity.
CITA DEL ARTÍCULO Radiother Oncol. 2016 Oct 13. pii: S0167-8140(16)34287-6. doi: 10.1016/j.radonc.2016.08.023